Evidence map›Paper›PMID 42196531›Full record

ReviewInternational journal of molecular sciences2026

Research Progress on the Mechanism of Ginsenosides in the Treatment of Parkinson's Disease.

Shanshan Wang, Zhi Chen, Haipeng Tang, Jiyu Gong, Kejin Xu, Kangyu Wang

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shanshan WangSchool of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun 130117, China.
Zhi ChenSchool of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun 130117, China.
Haipeng TangSchool of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun 130117, China.
Jiyu GongSchool of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun 130117, China.
Kejin XuSchool of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun 130117, China.
Kangyu WangSchool of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun 130117, China.

Funding

the Natural Science Foundation of Jilin Province YDZJ202401442ZYTS
6 · The paper itself

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder of the central nervous system with a complex pathogenesis. Current conventional medicines are predominantly symptomatic treatments, which fail to reverse neuronal degeneration and often induce severe motor complications following long-term administration. In this context, the advantages of the multi-target holistic regulation provided by traditional Chinese medicine have become increasingly prominent. As the core active ingredients of

Indexed as

GinsenosidesNeuroprotective AgentsParkinson DiseaseAnimalsHumansOxidative StressPanaxSapogeninsGinsenosidesNeuroprotective AgentsSapogeninsferroptosisginsenosidesmulti-target interventionneuroprotectionoxidative stresspanax ginsengParkinson’s diseaseprotopanaxadiolprotopanaxatriolα-synuclein

Identifiers

PMID42196531
PMCPMC13207488

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.